Biochemical characterization and in vitro activity of AZ513, a noncovalent, reversible, and noncompetitive inhibitor of fatty acid amide hydrolase

European Journal of Pharmacology

Volumn 667, Issue 1-3, 2011, Pages 74-79

  Scott, Clay W ^a   Tian, Gaochao ^a   Yu, Xiao Hong ^a   Paschetto, Kathy A ^a   Wilkins, Dee E ^a   Meury, Luc ^a   Cao, Chang Qing ^a   Varnes, Jeffrey ^a   Edwards, Philip D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Anandamide; Cannabinoids; CB 1 receptor; Enzyme inhibitor; Fatty acid amide hydrolase

Indexed keywords

2,3 DICHLORO N (1H PYRROLO[2,3 B]PYRIDIN 5 YL)BENZAMIDE; 7 PHENYL 1 [5 (2 PYRIDINYL) 2 OXAZOLYL] 1 HEPTANONE; ACETYLCHOLINESTERASE; AZ 513; CANNABINOID 1 RECEPTOR; ENDOCANNABINOID; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; THROMBIN; TRYPSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING COMPETITION; CELL ACTIVITY; CELL TRANSFER; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ASSAY; ENZYME INHIBITION; EXCITATORY POSTSYNAPTIC POTENTIAL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

AMIDOHYDROLASES; ANIMALS; BENZAMIDES; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME INHIBITORS; HEK293 CELLS; HUMANS; MALE; PATCH-CLAMP TECHNIQUES; PYRIMIDINES; PYRROLES; RATS; SPINAL CORD; SYNAPSES;

EID: 80052029740     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.05.052     Document Type: Article

References (44)

1. K. Ahn, D.S. Johnson, L.R. Fitzgerald, M. Liimatta, A. Arendse, T. Stevenson, E.T. Lund, R.A. Nugent, T.K. Nomanbhoy, J.P. Alexander, and B.F. Cravatt Novel mechanistic class of fatty acid amide hydrolase inhibitors with remarkable selectivity Biochemistry 46 2007 13019 13030 (Pubitemid 350086220)
2. K. Ahn, D.S. Johnson, and B.F. Cravatt Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders Expert Opin. Drug Discov. 4 2009 763 784
3. K. Ahn, D.S. Johnson, M. Mileni, D. Beidler, J.Z. Long, M.K. McKinney, E. Weerapana, N. Sadagopan, M. Liimatta, S.E. Smith, S. Lazerwith, C. Stiff, S. Kamtekar, K. Bhattacharya, Y. Zhang, S. Swaney, K. Van Becelaere, R.C. Stevens, and B.F. Cravatt Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain Chem. Biol. 16 2009 411 420
4. J.P. Alexander, and B.F. Cravatt Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes Chem. Biol. 12 2005 1179 1187 (Pubitemid 41628253)
5. J.S. Berman, C. Symonds, and R. Birch Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 112 2004 299 306 (Pubitemid 39550730)
6. M.H. Bracey, M.A. Hanson, K.R. Masuda, R.C. Stevens, and B.F. Cravatt Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling Science 298 2002 1793 1796 (Pubitemid 35404124)
7. D. Bridges, K. Ahmad, and A.S. Rice The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain Br. J. Pharmacol. 133 2001 586 594 (Pubitemid 32591925)
8. V. Di Marzo, A. Fontana, H. Cadas, S. Schinelli, G. Cimino, J.C. Schwartz, and D. Piomelli Formation and inactivation of endogenous cannabinoid anandamide in central neurons Nature 372 1994 686 691
9. E.K. Farrell, and D.J. Merkler Biosynthesis, degradation and pharmacological importance of the fatty acid amides Drug Discov. Today 13 2008 558 568
10. D. Fegley, S. Gaetani, A. Duranti, A. Tontini, M. Mor, G. Tarzia, and D. Piomelli Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation J. Pharmacol. Exp. Ther. 313 2005 352 358 (Pubitemid 40411361)
11. M. Feledziak, C. Michaux, A. Urbach, G. Labar, G.G. Muccioli, D.M. Lambert, and J. Marchand-Brynaert beta-Lactams derived from a carbapenem chiron are selective inhibitors of human fatty acid amide hydrolase versus human monoacylglycerol lipase J. Med. Chem. 52 2009 7054 7068
12. S. Gattinoni, C.D. Simone, S. Dallavalle, F. Fezza, R. Nannei, N. Battista, P. Minetti, G. Quattrociocchi, A. Caprioli, F. Borsini, W. Cabri, S. Penco, L. Merlini, and M. Maccarrone A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 20 2010 4406 4411
13. D.K. Giang, and B.F. Cravatt Molecular characterization of human and mouse fatty acid amide hydrolases Proc. Natl. Acad. Sci. U.S.A. 94 1997 2238 2242 (Pubitemid 27136858)
14. J. Guindon, and A.G. Hohmann The endocannabinoid system and pain CNS Neurol. Disord. Drug Targets 8 2009 403 421
15. K.L. Kage, P.L. Richardson, L. Traphagen, J. Severin, A. Pereda-Lopez, T. Lubben, R. Davis-Taber, M.H. Vos, D. Bartley, K. Walter, J. Harlan, L. Solomon, U. Warrior, T.F. Holzman, C. Faltynek, C.S. Surowy, and V.E. Scott A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase J. Neurosci. Meth. 161 2007 47 54 (Pubitemid 46357569)
16. M.J. Karbarz, L. Luo, L. Chang, C.S. Tham, J.A. Palmer, S.J. Wilson, M.L. Wennerholm, S.M. Brown, B.P. Scott, R.L. Apodaca, J.M. Keith, J. Wu, J.G. Breitenbucher, S.R. Chaplan, and M. Webb Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase Anesth. Analg. 108 2009 316 329
17. M. Karst, K. Salim, S. Burstein, I. Conrad, L. Hoy, and U. Schneider Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial JAMA 290 2003 1757 1762 (Pubitemid 37430626)
18. S.G. Kinsey, J.Z. Long, S.T. O'Neal, R.A. Abdullah, J.L. Poklis, D.L. Boger, B.F. Cravatt, and A.H. Lichtman Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain J. Pharmacol. Exp. Ther. 330 2009 902 910
19. K.S. Knappenberger, G. Tian, X. Ye, C. Sobotka-Briner, S.V. Ghanekar, B.D. Greenberg, and C.W. Scott Mechanism of gamma-secretase cleavage activation: is gamma-secretase regulated through autoinhibition involving the presenilin-1 exon 9 loop? Biochemistry 43 2004 6208 6218 (Pubitemid 38669489)
20. A.H. Lichtman, D. Leung, C.C. Shelton, A. Saghatelian, C. Hardouin, D.L. Boger, and B.F. Cravatt Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity J. Pharmacol. Exp. Ther. 311 2004 441 448 (Pubitemid 39391527)
21. M. Maccarrone, E. Dainese, and S. Oddi Intracellular trafficking of anandamide: new concepts for signaling Trends Biochem. Sci. 35 2010 601 608
22. B.R. Martin, and J.L. Wiley Mechanism of action of cannabinoids: how it may lead to treatment of cachexia, emesis, and pain J. Support. Oncol. 2 2004 305 314 (Pubitemid 39409773)
23. M.K. McKinney, and B.F. Cravatt Structure and function of fatty acid amide hydrolase Annu. Rev. Biochem. 74 2005 411 432 (Pubitemid 40995513)
24. M. Mileni, D.S. Johnson, Z. Wang, D.S. Everdeen, M. Liimatta, B. Pabst, K. Bhattacharya, R.A. Nugent, S. Kamtekar, B.F. Cravatt, K. Ahn, and R.C. Stevens Structure-guided inhibitor design for human FAAH by interspecies active site conversion Proc. Natl. Acad. Sci. U. S. A. 105 2008 12820 12824
25. M. Mileni, J. Garfunkle, J.K. DeMartino, B.F. Cravatt, D.L. Boger, and R.C. Stevens Binding and inactivation mechanism of a humanized fatty acid amide hydrolase by alpha-ketoheterocycle inhibitors revealed from cocrystal structures J. Am. Chem. Soc. 131 2009 10497 10506
26. A. Minkkila, S. Saario, and T. Nevalainen Discovery and development of endocannabinoid-hydrolyzing enzyme inhibitors Curr. Top. Med. Chem. 10 2010 828 858
27. V. Morisset, and L. Urban Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord J. Neurophysiol. 86 2001 40 48 (Pubitemid 32623210)
28. G.G. Muccioli Endocannabinoid biosynthesis and inactivation, from simple to complex Drug Discov. Today 15 2010 474 483
29. R. Nicholson, D. Spanswick, and K. Lee Nitric oxide inhibits NMDA currents in a subpopulation of substantia gelatinosa neurons of the adult rat spinal cord Neurosci. Lett. 359 2004 180 184 (Pubitemid 38446667)
30. Y. Okamoto, K. Tsuboi, and N. Ueda Enzymatic formation of anandamide Vitam. Horm. 81 2009 1 24
31. R.G. Pertwee Emerging strategies for exploiting cannabinoid receptor agonists as medicines Br. J. Pharmacol. 156 2009 397 411
32. R. Russo, J. Loverme, G. La Rana, T.R. Compton, J. Parrott, A. Duranti, A. Tontini, M. Mor, G. Tarzia, A. Calignano, and D. Piomelli The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′- carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice J. Pharmacol. Exp. Ther. 322 2007 236 242 (Pubitemid 46956375)
33. M. Seierstad, and J.G. Breitenbucher Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors J. Med. Chem. 51 2008 7327 7343
34. S.Y. Sit, C. Conway, R. Bertekap, K. Xie, C. Bourin, K. Burris, and H. Deng Novel inhibitors of fatty acid amide hydrolase Bioorg. Med. Chem. Lett. 17 2007 3287 3291 (Pubitemid 46830893)
35. R.Q. Skrabek, L. Galimova, K. Ethans, and D. Perry Nabilone for the treatment of pain in fibromyalgia J. Pain 9 2008 164 173
36. G. Tian, S.V. Ghanekar, D. Aharony, A.B. Shenvi, R.T. Jacobs, X. Liu, and B.D. Greenberg The mechanism of gamma-secretase: multiple inhibitor binding sites for transition state analogs and small molecule inhibitors J. Biol. Chem. 278 2003 28968 28975 (Pubitemid 36935808)
37. Tian, G., Paschetto, K.P., Gharahdaghi, F., Gordon, E., Wilkins, D.E., Luo, X., Scott, C., submitted for publication. Mechanism of Inhibition of Fatty Acid Amide Hydrolase by Sulfonamide Containing Benzothiazoles: Long Residence Time Derived from Increased Kinetic Barrier and Not Exclusively from Thermodynamic Potency.
38. J.M. Walker, and S.M. Huang Cannabinoid analgesia Pharmacol. Ther. 95 2002 127 135 (Pubitemid 35232131)
39. J. Wang, and N. Ueda Biology of endocannabinoid synthesis system Prostaglandins Other Lipid Mediat. 89 2009 112 119
40. Y. Wang, J. Xu, A. Uveges, M.K. Ramarao, K.E. Rogers, and P.G. Jones A novel scintillation proximity assay for fatty acid amide hydrolase compatible with inhibitor screening Anal. Biochem. 354 2006 35 42 (Pubitemid 43816392)
41. X. Wang, K. Sarris, K. Kage, D. Zhang, S.P. Brown, T. Kolasa, C. Surowy, O.F. El Kouhen, S.W. Muchmore, J.D. Brioni, and A.O. Stewart Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors J. Med. Chem. 52 2009 170 180
42. S. Wilson A high-throughput-compatible assay for determining the activity of fatty acid amide hydrolase Anal. Biochem. 318 2003 270 275 (Pubitemid 36694119)
43. J. Wissel, T. Haydn, J. Muller, C. Brenneis, T. Berger, W. Poewe, and L.D. Schelosky Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial J. Neurol. 253 2006 1337 1341 (Pubitemid 44691559)
44. M. Yoshimura, and T.M. Jessell Primary afferent-evoked synaptic responses and slow potential generation in rat substantia gelatinosa neurons in vitro J. Neurophysiol. 62 1989 96 108 (Pubitemid 19180544)